Estradiol; Norethindrone Acetate; Relugolix is Used for managing heavy menstrual bleeding and pain associated with uterine fibroids in premenopausal women, as well as pain associated with endometriosis. It was first introduced by Myovant Sciences Gmbh in its drug Myfembree on May 26, 2021.

Estradiol; Norethindrone Acetate; Relugolix Patents

Given below is the list of patents protecting Estradiol; Norethindrone Acetate; Relugolix, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Myfembree	US11033551	Methods of treating uterine fibroids	Sep 29, 2037	Myovant Sciences
Myfembree	US11793812	Methods of treating endometriosis	May 03, 2038	Myovant Sciences
Myfembree	US11795178	Compositions of thienopyrimidine derivatives	Sep 27, 2033	Myovant Sciences
Myfembree	US11957684	Treatment of heavy menstrual bleeding associated with uterine fibroids	Sep 29, 2037	Myovant Sciences
Myfembree	US7300935	Thienopyrimidine compounds and use thereof	Jan 28, 2025	Myovant Sciences
Myfembree	US8058280	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan 28, 2025	Myovant Sciences
Myfembree	US9346822	Thienopyrimidine compounds and use thereof	Feb 17, 2024 (Expired)	Myovant Sciences

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳